GCG and metabolic dysfunction-associated steatohepatitis: In phase 1 and 2 studies in patients with MASLD or MASH, liver fat reductions have been greatest with GLP-1/GIP/GCG triple agonists, GLP-1/GCG dual agonists and FGF21 analogs.